Study of a new drug for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that has spread to other parts of the body (like bones or lymph nodes).
- Your cancer got worse while on a next-generation hormone therapy (like abiraterone, enzalutamide, darolutamide, or apalutamide).
- You have not had chemotherapy for castration-resistant prostate cancer that has spread.
- You have either tried a PARP inhibitor, were told you cannot take one, or chose not to.
- You are still on hormone therapy (ADT) or have had your testicles removed, and your testosterone level is low enough.
- You are generally in good health (able to do your daily activities) and your organs are working well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.
This study tests an experimental drug, alone or with other treatments, for men with advanced prostate cancer that has stopped responding to standard therapies. The goal is to see if it can shrink tumors or slow the disease.
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.